<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>61085</id>
    <completedYear/>
    <publishedYear>2024</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>1</pageFirst>
    <pageLast>11</pageLast>
    <pageNumber/>
    <edition/>
    <issue>1</issue>
    <volume>14</volume>
    <type>article</type>
    <publisherName>Springer Science and Business Media LLC</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Elastin-specific MR probe for visualization and evaluation of an interleukin-1β targeted therapy for atherosclerosis</title>
    <abstract language="eng">Atherosclerosis is a chronic inflammatory condition of the arteries and represents the primary cause of various cardiovascular diseases. Despite ongoing progress, finding effective anti-inflammatory therapeutic strategies for atherosclerosis remains a challenge. Here, we assessed the potential of molecular magnetic resonance imaging (MRI) to visualize the effects of 01BSUR, an anti-interleukin-1β monoclonal antibody, for treating atherosclerosis in a murine model. Male apolipoprotein E-deficient mice were divided into a therapy group (01BSUR, 2 × 0.3 mg/kg subcutaneously, n = 10) and control group (no treatment, n = 10) and received a high-fat diet for eight weeks. The plaque burden was assessed using an elastin-targeted gadolinium-based contrast probe (0.2 mmol/kg intravenously) on a 3 T MRI scanner. T1-weighted imaging showed a significantly lower contrast-to-noise (CNR) ratio in the 01BSUR group (pre: 3.93042664; post: 8.4007067) compared to the control group (pre: 3.70679168; post: 13.2982156) following administration of the elastin-specific MRI probe (p &amp;lt; 0.05). Histological examinations demonstrated a significant reduction in plaque size (p &amp;lt; 0.05) and a significant decrease in plaque elastin content (p &amp;lt; 0.05) in the treatment group compared to control animals. This study demonstrated that 01BSUR hinders the progression of atherosclerosis in a mouse model. Using an elastin-targeted MRI probe, we could quantify these therapeutic effects in MRI.</abstract>
    <abstract language="deu">Atherosklerose ist eine chronische entzündliche Erkrankung der Arterien und die Hauptursache für verschiedene Herz-Kreislauf-Erkrankungen. Trotz kontinuierlicher Fortschritte ist es nach wie vor schwierig, wirksame entzündungshemmende Therapiestrategien für Atherosklerose zu finden. In dieser Studie haben wir das Potenzial der molekularen Magnetresonanztomographie (MRT) zur Visualisierung der Wirkung von 01BSUR, einem monoklonalen Anti-Interleukin-1β-Antikörper, zur Behandlung von Atherosklerose in einem Mausmodell untersucht. Männliche Apolipoprotein-E-defiziente Mäuse wurden in eine Therapiegruppe (01BSUR, 2 × 0,3 mg/kg subkutan, n = 10) und eine Kontrollgruppe (keine Behandlung, n = 10) aufgeteilt und erhielten acht Wochen lang eine fettreiche Diät. Die Plaquebelastung wurde mit einer auf Elastin ausgerichteten Kontrastmittelsonde auf Gadoliniumbasis (0,2 mmol/kg intravenös) auf einem 3-T-MRT-Scanner untersucht. Die T1-gewichtete Bildgebung zeigte ein signifikant niedrigeres Kontrast-Rausch-Verhältnis (CNR) in der 01BSUR-Gruppe (vorher: 3,93042664; nachher: 8,4007067) im Vergleich zur Kontrollgruppe (vorher: 3,70679168; nachher: 13,2982156) nach Verabreichung der Elastin-spezifischen MRT-Sonde (p &lt; 0,05). Histologische Untersuchungen zeigten eine signifikante Verringerung der Plaque-Größe (p &lt; 0,05) und eine signifikante Abnahme des Plaque-Elastin-Gehalts (p &lt; 0,05) in der Behandlungsgruppe im Vergleich zu den Kontrolltieren. Diese Studie zeigte, dass 01BSUR das Fortschreiten der Atherosklerose in einem Mausmodell hemmt. Mit einer auf Elastin ausgerichteten MRT-Sonde konnten wir diese therapeutischen Effekte in der MRT quantifizieren.</abstract>
    <parentTitle language="eng">Scientific Reports</parentTitle>
    <identifier type="doi">10.1038/s41598-024-71716-5</identifier>
    <identifier type="urn">urn:nbn:de:kobv:b43-610858</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_import_data">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:35:11Z","timestamp":1725496511298},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1340","SFB1340","SFB1340","SFB1340","SFB1340","SFB1340","SFB1340","SFB1340","SFB1340","SFB1340"],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG\/12\/1\/29262","RG\/12\/1\/29262"],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"&lt;jats:title&gt;Abstract&lt;\/jats:title&gt;&lt;jats:p&gt;Atherosclerosis is a chronic inflammatory condition of the arteries and represents the primary cause of various cardiovascular diseases. Despite ongoing progress, finding effective anti-inflammatory therapeutic strategies for atherosclerosis remains a challenge. Here, we assessed the potential of molecular magnetic resonance imaging (MRI) to visualize the effects of 01BSUR, an anti-interleukin-1\u03b2 monoclonal antibody, for treating atherosclerosis in a murine model. Male apolipoprotein E-deficient mice were divided into a therapy group (01BSUR, 2\u2009\u00d7\u20090.3\u00a0mg\/kg subcutaneously, n\u2009=\u200910) and control group (no treatment, n\u2009=\u200910) and received a high-fat diet for eight weeks. The plaque burden was assessed using an elastin-targeted gadolinium-based contrast probe (0.2\u00a0mmol\/kg intravenously) on a 3\u00a0T MRI scanner. T1-weighted imaging showed a significantly lower contrast-to-noise (CNR) ratio in the 01BSUR group (pre: 3.93042664; post: 8.4007067) compared to the control group (pre: 3.70679168; post: 13.2982156) following administration of the elastin-specific MRI probe (&lt;jats:italic&gt;p&lt;\/jats:italic&gt;\u2009&amp;lt;\u20090.05). Histological examinations demonstrated a significant reduction in plaque size (&lt;jats:italic&gt;p&lt;\/jats:italic&gt;\u2009&amp;lt;\u20090.05) and a significant decrease in plaque elastin content (&lt;jats:italic&gt;p&lt;\/jats:italic&gt;\u2009&amp;lt;\u20090.05) in the treatment group compared to control animals. This study demonstrated that 01BSUR hinders the progression of atherosclerosis in a mouse model. Using an elastin-targeted MRI probe, we could quantify these therapeutic effects in MRI.&lt;\/jats:p&gt;","DOI":"10.1038\/s41598-024-71716-5","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T20:29:45Z","timestamp":1725481785000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elastin-specific MR probe for visualization and evaluation of an interleukin-1\u03b2 targeted therapy for atherosclerosis"],"prefix":"10.1038","volume":"14","author":[{"given":"Dilyana Branimirova","family":"Mangarova","sequence":"first","affiliation":[]},{"given":"Carolin","family":"Reimann","sequence":"additional","affiliation":[]},{"given":"Jan Ole","family":"Kaufmann","sequence":"additional","affiliation":[]},{"given":"Jana","family":"M\u00f6ckel","sequence":"additional","affiliation":[]},{"given":"Avan","family":"Kader","sequence":"additional","affiliation":[]},{"given":"Lisa Christine","family":"Adams","sequence":"additional","affiliation":[]},{"given":"Antje","family":"Ludwig","sequence":"additional","affiliation":[]},{"given":"David","family":"Onthank","sequence":"additional","affiliation":[]},{"given":"Simon","family":"Robinson","sequence":"additional","affiliation":[]},{"given":"Uwe","family":"Karst","sequence":"additional","affiliation":[]},{"given":"Rebecca","family":"Helmer","sequence":"additional","affiliation":[]},{"given":"Rene","family":"Botnar","sequence":"additional","affiliation":[]},{"given":"Bernd","family":"Hamm","sequence":"additional","affiliation":[]},{"given":"Marcus Richard","family":"Makowski","sequence":"additional","affiliation":[]},{"given":"Julia","family":"Brangsch","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"71716_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/joim.12406","volume":"278","author":"GK Hansson","year":"2015","unstructured":"Hansson, G. K., Libby, P. &amp; Tabas, I. Inflammation and plaque vulnerability. J. Intern. Med. 278, 483\u2013493. https:\/\/doi.org\/10.1111\/joim.12406 (2015).","journal-title":"J. Intern. Med."},{"key":"71716_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby, P. The changing landscape of atherosclerosis. Nature 592, 524\u2013533. https:\/\/doi.org\/10.1038\/s41586-021-03392-8 (2021).","journal-title":"Nature"},{"key":"71716_CR3","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","volume":"47","author":"E Falk","year":"2006","unstructured":"Falk, E. Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol. 47, C7-12. https:\/\/doi.org\/10.1016\/j.jacc.2005.09.068 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"71716_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tcm.2018.05.010","volume":"29","author":"A Hartley","year":"2019","unstructured":"Hartley, A., Haskard, D. &amp; Khamis, R. Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis-novel insights and future directions in diagnosis and therapy&lt;sup\/&gt;. Trends Cardiovasc. Med. 29, 22\u201326. https:\/\/doi.org\/10.1016\/j.tcm.2018.05.010 (2019).","journal-title":"Trends Cardiovasc. Med."},{"key":"71716_CR5","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1093\/cvr\/cvab337","volume":"118","author":"J Hettwer","year":"2022","unstructured":"Hettwer, J. et al. Interleukin-1beta suppression dampens inflammatory leucocyte production and uptake in atherosclerosis. Cardiovasc. Res. 118, 2778\u20132791. https:\/\/doi.org\/10.1093\/cvr\/cvab337 (2022).","journal-title":"Cardiovasc. Res."},{"key":"71716_CR6","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","volume":"122","author":"A Grebe","year":"2018","unstructured":"Grebe, A., Hoss, F. &amp; Latz, E. NLRP3 inflammasome and the il-1 pathway in atherosclerosis. Circ. Res. 122, 1722\u20131740. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311362 (2018).","journal-title":"Circ. Res."},{"key":"71716_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000250095","volume":"47","author":"AW Orr","year":"2010","unstructured":"Orr, A. W., Hastings, N. E., Blackman, B. R. &amp; Wamhoff, B. R. Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J. Vasc. Res. 47, 168\u2013180. https:\/\/doi.org\/10.1159\/000250095 (2010).","journal-title":"J. Vasc. Res."},{"key":"71716_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914 (2017).","journal-title":"N. Engl. J. Med."},{"key":"71716_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial. Lancet 391, 319\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(17)32814-3 (2018).","journal-title":"Lancet"},{"key":"71716_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/19420862.2015.1081323","volume":"7","author":"JM Rondeau","year":"2015","unstructured":"Rondeau, J. M., Ramage, P., Zurini, M. &amp; Gram, H. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta. MAbs 7, 1151\u20131160. https:\/\/doi.org\/10.1080\/19420862.2015.1081323 (2015).","journal-title":"MAbs"},{"key":"71716_CR11","doi-asserted-by":"publisher","first-page":"153601212096187","DOI":"10.1177\/1536012120961875","volume":"19","author":"J Brangsch","year":"2020","unstructured":"Brangsch, J. et al. Molecular MR-imaging for noninvasive quantification of the anti-inflammatory effect of targeting interleukin-1beta in a mouse model of aortic aneurysm. Mol. Imaging 19, 1536012120961875. https:\/\/doi.org\/10.1177\/1536012120961875 (2020).","journal-title":"Mol. Imaging"},{"key":"71716_CR12","doi-asserted-by":"publisher","first-page":"e1206","DOI":"10.1002\/cti2.1206","volume":"9","author":"D Dragoljevic","year":"2020","unstructured":"Dragoljevic, D. et al. Inhibition of interleukin-1beta signalling promotes atherosclerotic lesion remodelling in mice with inflammatory arthritis. Clin. Transl. Immunol. 9, e1206. https:\/\/doi.org\/10.1002\/cti2.1206 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"71716_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.5551\/jat.10.267","volume":"10","author":"S Katsuda","year":"2003","unstructured":"Katsuda, S. &amp; Kaji, T. Atherosclerosis and extracellular matrix. J. Atheroscler. Thromb. 10, 267\u2013274. https:\/\/doi.org\/10.5551\/jat.10.267 (2003).","journal-title":"J. Atheroscler. Thromb."},{"key":"71716_CR14","doi-asserted-by":"publisher","first-page":"C875","DOI":"10.1152\/ajpcell.00448.2021","volume":"322","author":"CJ Lin","year":"2022","unstructured":"Lin, C. J., Cocciolone, A. J. &amp; Wagenseil, J. E. Elastin, arterial mechanics, and stenosis. Am. J. Physiol. Cell Physiol. 322, C875\u2013C886. https:\/\/doi.org\/10.1152\/ajpcell.00448.2021 (2022).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"71716_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1161\/01.ATV.0000064372.78561.A5","volume":"23","author":"A Krettek","year":"2003","unstructured":"Krettek, A., Sukhova, G. K. &amp; Libby, P. Elastogenesis in human arterial disease: A role for macrophages in disordered elastin synthesis. Arterioscler. Thromb. Vasc. Biol. 23, 582\u2013587. https:\/\/doi.org\/10.1161\/01.ATV.0000064372.78561.A5 (2003).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"71716_CR16","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/eurheartj\/ehu041","volume":"36","author":"C Van der Donckt","year":"2015","unstructured":"Van der Donckt, C. et al. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. Eur. Heart J. 36, 1049\u20131058. https:\/\/doi.org\/10.1093\/eurheartj\/ehu041 (2015).","journal-title":"Eur. Heart J."},{"key":"71716_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/cvr\/cvt336","volume":"102","author":"S Gayral","year":"2014","unstructured":"Gayral, S. et al. Elastin-derived peptides potentiate atherosclerosis through the immune Neu1-PI3Kgamma pathway. Cardiovasc. Res. 102, 118\u2013127. https:\/\/doi.org\/10.1093\/cvr\/cvt336 (2014).","journal-title":"Cardiovasc. Res."},{"key":"71716_CR18","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1253\/circj.cj-09-0104","volume":"73","author":"T Akima","year":"2009","unstructured":"Akima, T. et al. Soluble elastin decreases in the progress of atheroma formation in human aorta. Circ. J. 73, 2154\u20132162. https:\/\/doi.org\/10.1253\/circj.cj-09-0104 (2009).","journal-title":"Circ. J."},{"key":"71716_CR19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.106.655423","volume":"116","author":"D Onthank","year":"2007","unstructured":"Onthank, D. et al. BMS753951: A novel low molecular weight magnetic resonance contrast agent selective for arterial wall imaging. Circulation 116, 411\u2013412 (2007).","journal-title":"Circulation"},{"key":"71716_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nm.2310","volume":"17","author":"MR Makowski","year":"2011","unstructured":"Makowski, M. R. et al. Assessment of atherosclerotic plaque burden with an elastin-specific magnetic resonance contrast agent. Nat. Med. 17, 383\u2013388. https:\/\/doi.org\/10.1038\/nm.2310 (2011).","journal-title":"Nat. Med."},{"key":"71716_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1148\/radiol.13130502","volume":"271","author":"A Phinikaridou","year":"2014","unstructured":"Phinikaridou, A. et al. Vascular remodeling and plaque vulnerability in a rabbit model of atherosclerosis: Comparison of delayed-enhancement MR imaging with an elastin-specific contrast agent and unenhanced black-blood MR imaging. Radiology 271, 390\u2013399. https:\/\/doi.org\/10.1148\/radiol.13130502 (2014).","journal-title":"Radiology"},{"key":"71716_CR22","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1016\/S0021-9258(18)53281-6","volume":"268","author":"A Mauviel","year":"1993","unstructured":"Mauviel, A. et al. Human recombinant interleukin-1 beta up-regulates elastin gene expression in dermal fibroblasts. Evidence for transcriptional regulation in vitro and in vivo. J. Biol. Chem. 268, 6520\u20136524 (1993).","journal-title":"J. Biol. Chem."},{"key":"71716_CR23","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1093\/eurheartj\/ehz008","volume":"40","author":"A Vromman","year":"2019","unstructured":"Vromman, A. et al. Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis. Eur. Heart J. 40, 2482\u20132491. https:\/\/doi.org\/10.1093\/eurheartj\/ehz008 (2019).","journal-title":"Eur. Heart J."},{"key":"71716_CR24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello, C. A., Simon, A. &amp; van der Meer, J. W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633\u2013652. https:\/\/doi.org\/10.1038\/nrd3800 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"71716_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.11.026","volume":"195","author":"Y Kamari","year":"2007","unstructured":"Kamari, Y. et al. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 195, 31\u201338. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.11.026 (2007).","journal-title":"Atherosclerosis"},{"key":"71716_CR26","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","volume":"23","author":"H Kirii","year":"2003","unstructured":"Kirii, H. et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 656\u2013660. https:\/\/doi.org\/10.1161\/01.ATV.0000064374.15232.C3 (2003).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"71716_CR27","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1161\/01.ATV.0000127025.48140.a3","volume":"24","author":"K Isoda","year":"2004","unstructured":"Isoda, K. et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 24, 1068\u20131073. https:\/\/doi.org\/10.1161\/01.ATV.0000127025.48140.a3 (2004).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"71716_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1172\/JCI118476","volume":"97","author":"H Shimokawa","year":"1996","unstructured":"Shimokawa, H. et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J. Clin. Invest. 97, 769\u2013776. https:\/\/doi.org\/10.1172\/JCI118476 (1996).","journal-title":"J. Clin. Invest."},{"key":"71716_CR29","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41591-018-0124-5","volume":"24","author":"D Gomez","year":"2018","unstructured":"Gomez, D. et al. Interleukin-1beta has atheroprotective effects in advanced atherosclerotic lesions of mice. Nat. Med. 24, 1418\u20131429. https:\/\/doi.org\/10.1038\/s41591-018-0124-5 (2018).","journal-title":"Nat. Med."},{"key":"71716_CR30","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1912388 (2019).","journal-title":"N. Engl. J. Med."},{"key":"71716_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1083\/jcb.25.1.145","volume":"25","author":"EW Taylor","year":"1965","unstructured":"Taylor, E. W. The mechanism of colchicine inhibition of mitosis. I. Kinetics of inhibition and the binding of H3-colchicine. J. Cell Biol. 25, 145\u2013160. https:\/\/doi.org\/10.1083\/jcb.25.1.145 (1965).","journal-title":"J. Cell Biol."},{"key":"71716_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. &amp; Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241. https:\/\/doi.org\/10.1038\/nature04516 (2006).","journal-title":"Nature"},{"key":"71716_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12265-020-09974-7","volume":"14","author":"A Cecconi","year":"2021","unstructured":"Cecconi, A. et al. Effects of colchicine on atherosclerotic plaque stabilization: A multimodality imaging study in an animal model. J. Cardiovasc. Transl. Res. 14, 150\u2013160. https:\/\/doi.org\/10.1007\/s12265-020-09974-7 (2021).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"71716_CR34","doi-asserted-by":"publisher","first-page":"e001492","DOI":"10.1136\/openhrt-2020-001492","volume":"8","author":"R Helseth","year":"2021","unstructured":"Helseth, R. et al. Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction. Open Heart 8, e001492. https:\/\/doi.org\/10.1136\/openhrt-2020-001492 (2021).","journal-title":"Open Heart"},{"key":"71716_CR35","doi-asserted-by":"publisher","first-page":"104013","DOI":"10.1016\/j.ebiom.2022.104013","volume":"80","author":"C Huse","year":"2022","unstructured":"Huse, C. et al. Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. EBioMedicine 80, 104013. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104013 (2022).","journal-title":"EBioMedicine"},{"key":"71716_CR36","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752\u2013762. https:\/\/doi.org\/10.1056\/NEJMoa1809798 (2019).","journal-title":"N. Engl. J. Med."},{"key":"71716_CR37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ejvs.2020.08.032","volume":"60","author":"LL Guo","year":"2020","unstructured":"Guo, L. L. et al. Blocking interleukin-1 beta reduces the evolution of thoracic aortic dissection in a rodent model. Eur. J. Vasc. Endovasc. Surg. 60, 916\u2013924. https:\/\/doi.org\/10.1016\/j.ejvs.2020.08.032 (2020).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"71716_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/icvts\/ivy256","volume":"28","author":"YF Jiang","year":"2019","unstructured":"Jiang, Y. F. et al. Local upregulation of interleukin-1 beta in aortic dissecting aneurysm: Correlation with matrix metalloproteinase-2, 9 expression and biomechanical decrease. Interact. Cardiovasc. Thorac. Surg. 28, 344\u2013352. https:\/\/doi.org\/10.1093\/icvts\/ivy256 (2019).","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"71716_CR39","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1161\/CIRCULATIONAHA.113.006800","volume":"130","author":"WF Johnston","year":"2014","unstructured":"Johnston, W. F. et al. Inhibition of interleukin-1beta decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms. Circulation 130, S51-59. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.006800 (2014).","journal-title":"Circulation"},{"key":"71716_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cardiores.2005.01.008","volume":"66","author":"F Merhi-Soussi","year":"2005","unstructured":"Merhi-Soussi, F. et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res. 66, 583\u2013593. https:\/\/doi.org\/10.1016\/j.cardiores.2005.01.008 (2005).","journal-title":"Cardiovasc. Res."},{"key":"71716_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tcm.2012.12.004","volume":"23","author":"P Maurice","year":"2013","unstructured":"Maurice, P. et al. Elastin fragmentation and atherosclerosis progression: The elastokine concept. Trends Cardiovasc. Med. 23, 211\u2013221. https:\/\/doi.org\/10.1016\/j.tcm.2012.12.004 (2013).","journal-title":"Trends Cardiovasc. Med."},{"key":"71716_CR42","doi-asserted-by":"publisher","first-page":"eaat4865","DOI":"10.1126\/scitranslmed.aat4865","volume":"11","author":"Q Sun","year":"2019","unstructured":"Sun, Q. et al. Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis. Sci. Transl. Med. 11, eaat4865. https:\/\/doi.org\/10.1126\/scitranslmed.aat4865 (2019).","journal-title":"Sci. Transl. Med."},{"key":"71716_CR43","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.1038\/s41598-021-86417-6","volume":"11","author":"F Collettini","year":"2021","unstructured":"Collettini, F. et al. Elastin-specific MRI of extracellular matrix-remodelling following hepatic radiofrequency-ablation in a VX2 liver tumor model. Sci. Rep. 11, 6814. https:\/\/doi.org\/10.1038\/s41598-021-86417-6 (2021).","journal-title":"Sci. Rep."},{"key":"71716_CR44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.acthis.2006.07.002","volume":"108","author":"R Coleman","year":"2006","unstructured":"Coleman, R., Hayek, T., Keidar, S. &amp; Aviram, M. A mouse model for human atherosclerosis: Long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice. Acta Histochem. 108, 415\u2013424. https:\/\/doi.org\/10.1016\/j.acthis.2006.07.002 (2006).","journal-title":"Acta Histochem."},{"key":"71716_CR45","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.6061\/clinics\/2012(09)15","volume":"67","author":"ML Ferraz","year":"2012","unstructured":"Ferraz, M. L. et al. Correlation of lifetime progress of atherosclerosis and morphologic markers of severity in humans: New tools for a more sensitive evaluation. Clinics (Sao Paulo) 67, 1071\u20131075. https:\/\/doi.org\/10.6061\/clinics\/2012(09)15 (2012).","journal-title":"Clinics (Sao Paulo)"},{"key":"71716_CR46","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1172\/JCI6172","volume":"103","author":"C Knouff","year":"1999","unstructured":"Knouff, C. et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J. Clin. Invest. 103, 1579\u20131586. https:\/\/doi.org\/10.1172\/JCI6172 (1999).","journal-title":"J. Clin. Invest."},{"issue":"Suppl","key":"71716_CR47","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1194\/jlr.R800070-JLR200","volume":"50","author":"AA Pendse","year":"2009","unstructured":"Pendse, A. A., Arbones-Mainar, J. M., Johnson, L. A., Altenburg, M. K. &amp; Maeda, N. Apolipoprotein E knock-out and knock-in mice: Atherosclerosis, metabolic syndrome, and beyond. J. Lipid Res. 50(Suppl), S178-182. https:\/\/doi.org\/10.1194\/jlr.R800070-JLR200 (2009).","journal-title":"J. Lipid Res."},{"key":"71716_CR48","first-page":"309","volume":"61","author":"DD Smith","year":"2010","unstructured":"Smith, D. D. et al. Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production. J. Physiol. Pharmacol. 61, 309\u2013316 (2010).","journal-title":"J. Physiol. Pharmacol."},{"key":"71716_CR49","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2021.35.S1.04018","author":"A Centner","year":"2021","unstructured":"Centner, A. et al. Sex differences in atherosclerosis in ApoE-\/- mice exposed to nicotine and cigarette smoke. Faseb J. https:\/\/doi.org\/10.1096\/fasebj.2021.35.S1.04018 (2021).","journal-title":"Faseb J."},{"key":"71716_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijcard.2018.05.072","volume":"270","author":"K Isoda","year":"2018","unstructured":"Isoda, K. et al. Inhibition of interleukin-1 suppresses angiotensin II-induced aortic inflammation and aneurysm formation. Int. J. Cardiol. 270, 221\u2013227. https:\/\/doi.org\/10.1016\/j.ijcard.2018.05.072 (2018).","journal-title":"Int. J. Cardiol."},{"key":"71716_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/0003319715583205","volume":"67","author":"Z Awan","year":"2016","unstructured":"Awan, Z. et al. Reducing vascular calcification by anti-IL-1\u03b2 monoclonal antibody in a mouse model of familial hypercholesterolemia. Angiology 67, 157\u2013167. https:\/\/doi.org\/10.1177\/0003319715583205 (2016).","journal-title":"Angiology"},{"key":"71716_CR52","first-page":"515","volume":"11","author":"T Geiger","year":"1993","unstructured":"Geiger, T. et al. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA\/1 mice and prevents the associated acute-phase response. Clin. Exp. Rheumatol. 11, 515\u2013522 (1993).","journal-title":"Clin. Exp. Rheumatol."},{"key":"71716_CR53","doi-asserted-by":"publisher","first-page":"13827","DOI":"10.1038\/s41598-019-50100-8","volume":"9","author":"C Reimann","year":"2019","unstructured":"Reimann, C. et al. Dual-probe molecular MRI for the in vivo characterization of atherosclerosis in a mouse model: Simultaneous assessment of plaque inflammation and extracellular-matrix remodeling. Sci. Rep. 9, 13827. https:\/\/doi.org\/10.1038\/s41598-019-50100-8 (2019).","journal-title":"Sci. Rep."},{"key":"71716_CR54","doi-asserted-by":"publisher","first-page":"e008707","DOI":"10.1161\/CIRCIMAGING.118.008707","volume":"12","author":"J Brangsch","year":"2019","unstructured":"Brangsch, J. et al. Concurrent molecular magnetic resonance imaging of inflammatory activity and extracellular matrix degradation for the prediction of aneurysm rupture. Circ. Cardiovasc. Imaging 12, e008707. https:\/\/doi.org\/10.1161\/CIRCIMAGING.118.008707 (2019).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"71716_CR55","doi-asserted-by":"publisher","first-page":"15206","DOI":"10.1038\/s41598-020-71817-x","volume":"10","author":"LC Adams","year":"2020","unstructured":"Adams, L. C. et al. Simultaneous molecular MRI of extracellular matrix collagen and inflammatory activity to predict abdominal aortic aneurysm rupture. Sci. Rep. 10, 15206. https:\/\/doi.org\/10.1038\/s41598-020-71817-x (2020).","journal-title":"Sci. Rep."},{"key":"71716_CR56","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1038\/s41598-020-59842-2","volume":"10","author":"LC Adams","year":"2020","unstructured":"Adams, L. C. et al. Noninvasive imaging of vascular permeability to predict the risk of rupture in abdominal aortic aneurysms using an albumin-binding probe. Sci. Rep. 10, 3231. https:\/\/doi.org\/10.1038\/s41598-020-59842-2 (2020).","journal-title":"Sci. Rep."},{"key":"71716_CR57","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCIMAGING.113.001131","volume":"7","author":"RM Botnar","year":"2014","unstructured":"Botnar, R. M. et al. In vivo assessment of aortic aneurysm wall integrity using elastin-specific molecular magnetic resonance imaging. Circ. Cardiovasc. Imaging 7, 679\u2013689. https:\/\/doi.org\/10.1161\/CIRCIMAGING.113.001131 (2014).","journal-title":"Circ. Cardiovasc. Imaging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71716-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71716-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71716-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T20:31:02Z","timestamp":1725481862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71716-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71716"],"URL":"http:\/\/dx.doi.org\/10.1038\/s41598-024-71716-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The elastin-specific contrast agent was provided by Lantheus Medical Imaging, North Billerica, Massachusetts, USA. S.R. and D.O. are employees of Lantheus Medical Imaging. The remaining authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20648"}}</enrichment>
    <enrichment key="local_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="date_peer_review">23.09.2024</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Dilyana Branimirova Mangarova</author>
    <author>Carolin Reimann</author>
    <author>Jan Ole Kaufmann</author>
    <author>Jana Möckel</author>
    <author>Avan Kader</author>
    <author>Lisa Christine Adams</author>
    <author>Antje Ludwig</author>
    <author>David Onthank</author>
    <author>Simon Robinson</author>
    <author>Uwe Karst</author>
    <author>Rebecca Helmer</author>
    <author>Rene Botnar</author>
    <author>Bernd Hamm</author>
    <author>Marcus Richard Makowski</author>
    <author>Julia Brangsch</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Atherosclerosis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Molecular imaging</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Elastin</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Plaque</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Interleukin-1beta</value>
    </subject>
    <collection role="ddc" number="543">Analytische Chemie</collection>
    <collection role="institutes" number="">1 Analytische Chemie; Referenzmaterialien</collection>
    <collection role="institutes" number="">1.5 Proteinanalytik</collection>
    <collection role="themenfelder" number="">Chemie und Prozesstechnik</collection>
    <collection role="themenfelder" number="">Chemische Charakterisierung und Spurenanalytik</collection>
    <collection role="literaturgattung" number="">Verlagsliteratur</collection>
    <collection role="fulltextaccess" number="">Datei für die Öffentlichkeit verfügbar ("Open Access")</collection>
    <collection role="unnumberedseries" number="">Wissenschaftliche Artikel der BAM</collection>
    <thesisPublisher>Bundesanstalt für Materialforschung und -prüfung (BAM)</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-bam/files/61085/Mangarova-2024-SciRep.pdf</file>
  </doc>
</export-example>
